WVE
Wave Life Sciences Ltd. NASDAQ Listed Nov 11, 2015$7.24
Mkt Cap $1.4B
52w Low $5.02
13.3% of range
52w High $21.73
50d MA $9.65
200d MA $10.20
P/E (TTM)
-6.0x
EV/EBITDA
-11.7x
P/B
2.4x
Debt/Equity
0.0x
ROE
-35.9%
P/FCF
-15.3x
RSI (14)
—
ATR (14)
—
Beta
-1.32
50d MA
$9.65
200d MA
$10.20
Avg Volume
4.2M
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
Marina One East Tower · Singapore, U0 018936 · SG
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | TNS | -0.34 | -0.13 | +61.8% | 7.52 | -1.6% | -6.2% | -6.1% | -2.7% | -0.7% | -2.9% | — |
| Feb 26, 2026 | TNS | -0.28 | -0.30 | -7.1% | 15.36 | -1.8% | -9.3% | -9.8% | -12.5% | -10.7% | -14.1% | — |
| Nov 10, 2025 | TNS | -0.30 | -0.32 | -6.7% | 7.05 | -0.7% | +3.0% | -1.3% | -5.4% | +0.4% | +1.4% | — |
| Jul 30, 2025 | TNS | -0.29 | -0.31 | -6.9% | 8.16 | -1.6% | -0.7% | +5.8% | +7.2% | +8.3% | +4.8% | — |
| May 8, 2025 | TNS | -0.27 | -0.29 | -7.4% | 6.54 | -0.2% | +0.8% | +0.9% | -2.3% | -2.9% | -3.7% | — |
| Mar 4, 2025 | TNS | -0.17 | 0.17 | +200.0% | 11.23 | -0.9% | -5.9% | -9.3% | -16.3% | -16.4% | -7.4% | — |
| Nov 12, 2024 | TNS | -0.28 | -0.47 | -67.9% | 15.89 | +2.6% | -1.3% | -5.6% | -14.0% | -19.1% | -10.6% | — |
| Aug 8, 2024 | TNS | -0.21 | -0.25 | -19.0% | 5.74 | +0.2% | -5.7% | -6.4% | -3.0% | -3.0% | +1.2% | — |
| May 9, 2024 | TNS | -0.21 | -0.24 | -14.3% | 5.76 | +2.4% | -2.4% | -1.2% | +1.4% | +2.4% | +2.4% | — |
| Mar 6, 2024 | TNS | -0.23 | -0.15 | +34.8% | 6.29 | +1.7% | +8.4% | +7.8% | +8.1% | +5.9% | +8.7% | — |
| Nov 9, 2023 | TNS | -0.18 | 0.07 | +138.9% | 5.21 | -1.0% | +0.8% | -0.4% | +4.4% | +4.2% | +5.4% | — |
| Aug 3, 2023 | TNS | -0.33 | -0.20 | +39.4% | 5.06 | +1.6% | -1.2% | -9.3% | -11.1% | -12.3% | -8.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.05 | $7.05 | +0.0% | +0.1% | +3.8% | +6.0% | +1.8% | +3.4% |
| Apr 29 | Truist | Reiterates | Buy | $15 | $7.52 | $7.40 | -1.6% | -6.2% | -6.1% | -2.7% | -0.7% | -4.5% |
| Apr 29 | Truist | Maintains | Buy → Buy | — | $7.52 | $7.40 | -1.6% | -6.2% | -6.1% | -2.7% | -0.7% | -4.5% |
| Apr 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.26 | $7.29 | +0.4% | +1.8% | +4.5% | +0.8% | +3.2% | +4.4% |
| Mar 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $6.20 | $6.02 | -2.9% | +2.7% | +6.8% | +16.9% | +10.2% | +17.4% |
| Mar 27 | BofA Securities | Maintains | Buy → Buy | — | $6.20 | $6.02 | -2.9% | +2.7% | +6.8% | +16.9% | +10.2% | +17.4% |
| Mar 25 | Mizuho | Maintains | Outperform → Outperform | — | $11.63 | $12.18 | +4.7% | +5.8% | -46.7% | -45.2% | -43.1% | -37.7% |
| Mar 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $13.29 | $13.54 | +1.9% | +3.5% | +5.9% | +0.5% | -2.0% | -6.6% |
| Mar 6 | Wedbush | Maintains | Outperform → Outperform | — | $13.20 | $13.22 | +0.2% | -0.6% | +0.7% | +4.2% | +6.7% | +1.1% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.93 | $13.65 | -2.0% | -0.6% | -3.5% | -1.6% | -5.2% | -5.8% |
| Feb 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $13.27 | $13.19 | -0.6% | -3.5% | -4.4% | -5.1% | -1.4% | -0.8% |
| Feb 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $13.33 | $13.37 | +0.3% | -4.4% | +0.9% | +2.6% | +2.0% | -0.5% |
| Feb 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $13.43 | $13.55 | +0.9% | +2.0% | -0.7% | -5.1% | +0.1% | +1.8% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.54 | $15.53 | -0.1% | +2.8% | +15.6% | +12.5% | +17.4% | +14.4% |
| Dec 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $16.11 | $16.80 | +4.3% | +1.9% | +1.4% | -3.5% | -0.8% | +11.5% |
| Dec 15 | Truist | Maintains | Buy → Buy | — | $16.56 | $16.75 | +1.1% | -2.7% | -0.9% | -1.3% | -6.2% | -3.5% |
| Dec 12 | Wedbush | Maintains | Outperform → Outperform | — | $16.75 | $17.38 | +3.8% | -1.1% | -3.8% | -2.0% | -2.4% | -7.2% |
| Dec 12 | B. Riley Securities | Maintains | Buy → Buy | — | $16.75 | $17.38 | +3.8% | -1.1% | -3.8% | -2.0% | -2.4% | -7.2% |
| Dec 9 | Wells Fargo | Maintains | Overweight → Overweight | — | $18.52 | $19.90 | +7.5% | +15.1% | +9.2% | -9.6% | -10.6% | -13.0% |
| Dec 9 | Clear Street | Maintains | Buy → Buy | — | $18.52 | $19.90 | +7.5% | +15.1% | +9.2% | -9.6% | -10.6% | -13.0% |
| Dec 9 | Citigroup | Maintains | Buy → Buy | — | $18.52 | $19.90 | +7.5% | +15.1% | +9.2% | -9.6% | -10.6% | -13.0% |
| Dec 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $18.52 | $19.90 | +7.5% | +15.1% | +9.2% | -9.6% | -10.6% | -13.0% |
| Dec 9 | Canaccord Genuity | Maintains | Buy → Buy | — | $18.52 | $19.90 | +7.5% | +15.1% | +9.2% | -9.6% | -10.6% | -13.0% |
| Dec 9 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $18.52 | $19.90 | +7.5% | +15.1% | +9.2% | -9.6% | -10.6% | -13.0% |
| Nov 11 | Wedbush | Maintains | Outperform → Outperform | — | $7.05 | $7.00 | -0.7% | +3.0% | -1.3% | -5.4% | +0.4% | +1.4% |
| Nov 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $7.05 | $7.00 | -0.7% | +3.0% | -1.3% | -5.4% | +0.4% | +1.4% |
| Sep 4 | Wells Fargo | Maintains | Overweight → Overweight | — | $8.00 | $8.00 | +0.0% | +2.2% | +3.6% | -5.2% | -6.5% | -7.6% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.62 | $7.39 | -23.2% | -16.8% | -15.0% | -13.8% | -21.2% | -22.2% |
| Jul 31 | Wells Fargo | Maintains | Overweight → Overweight | — | $8.16 | $8.03 | -1.6% | -0.7% | +5.8% | +7.2% | +8.3% | +4.8% |
| Jun 23 | Wedbush | Maintains | Outperform → Outperform | — | $6.57 | $6.47 | -1.5% | +5.9% | +4.0% | +4.3% | +7.0% | +1.5% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.44 | $10.73 | +13.7% | +6.1% | -4.6% | -8.7% | -14.4% | -18.0% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.23 | $11.13 | -0.9% | -5.9% | -9.3% | -16.3% | -16.4% | -7.4% |
| Nov 21 | Mizuho | Maintains | Outperform → Outperform | — | $14.26 | $14.24 | -0.1% | +0.6% | +0.1% | +4.4% | +4.0% | +5.1% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.89 | $16.31 | +2.6% | -1.3% | -5.6% | -14.0% | -19.1% | -10.6% |
| Nov 12 | Truist | Maintains | Buy → Buy | — | $16.44 | $14.97 | -8.9% | -3.3% | -4.6% | -8.8% | -16.8% | -21.8% |
| Nov 4 | B. Riley Securities | Maintains | Buy → Buy | — | $13.83 | $13.85 | +0.1% | -0.3% | +0.1% | +2.7% | +7.2% | +18.9% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.32 | $14.14 | -1.3% | -4.3% | -3.4% | -3.7% | -3.4% | -0.8% |
| Oct 21 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $15.31 | $15.07 | -1.6% | -1.3% | -3.1% | -4.2% | -3.2% | -5.6% |
| Oct 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.90 | $14.78 | -0.8% | -1.9% | +2.8% | +1.4% | -0.5% | -1.5% |
| Oct 17 | JP Morgan | Maintains | Overweight → Overweight | — | $14.90 | $14.78 | -0.8% | -1.9% | +2.8% | +1.4% | -0.5% | -1.5% |
| Oct 16 | Leerink Partners | Maintains | Outperform → Outperform | — | $8.56 | $12.05 | +40.8% | +74.1% | +70.7% | +78.9% | +76.5% | +73.2% |
| Oct 16 | Wells Fargo | Maintains | Overweight → Overweight | — | $8.56 | $12.05 | +40.8% | +74.1% | +70.7% | +78.9% | +76.5% | +73.2% |
| Oct 16 | Raymond James | Upgrade | Outperform → Strong Buy | — | $8.56 | $12.05 | +40.8% | +74.1% | +70.7% | +78.9% | +76.5% | +73.2% |
| Oct 4 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $8.50 | $8.56 | +0.7% | -1.1% | -5.4% | -5.9% | -1.1% | -2.8% |
| Oct 3 | B. Riley Securities | Maintains | Buy → Buy | — | $8.83 | $8.95 | +1.4% | -3.7% | -4.8% | -8.9% | -9.4% | -4.8% |
| Sep 25 | Jones Trading | Maintains | Buy → Buy | — | $8.19 | $8.50 | +3.8% | +10.0% | -2.1% | +1.2% | +0.1% | +1.3% |
| Sep 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.19 | $8.50 | +3.8% | +10.0% | -2.1% | +1.2% | +0.1% | +1.3% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.77 | $4.63 | -2.9% | -8.2% | +4.6% | +4.6% | +9.9% | +9.4% |
| Jun 25 | Mizuho | Maintains | Outperform → Outperform | — | $5.21 | $5.14 | -1.3% | -8.4% | -15.9% | -4.2% | -4.2% | +0.6% |
| Apr 1 | Truist | Maintains | Buy → Buy | — | $6.17 | $6.21 | +0.6% | +2.3% | +1.3% | -3.7% | -5.2% | -4.2% |
No insider trades available.
8-K
Wave Life Sciences Ltd. -- 8-K Filing
Wave Life Sciences issued a press release as disclosed in its 8-K filing, though the specific announcement details require review of the attached exhibit for investor impact assessment.
Apr 28
8-K
Wave Life Sciences Ltd. -- 8-K Filing
Wave Life Sciences filed a proxy statement regarding Wave-Singapore, indicating shareholders will vote on a significant corporate action, with documents available on the SEC and company websites.
Apr 21
8-K
Unknown — 8-K Filing
Wave Life Sciences is redomiciling from Singapore to Delaware, likely improving U.S. investor accessibility and corporate governance, which could enhance stock liquidity and institutional investment appeal.
Apr 15
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
WVE announced a material event via press release, likely involving significant business developments or financial results that could materially impact the stock's price and warrant immediate investor review of the full announcement.
Mar 26
8-K
Wave Life Sciences Ltd. -- 8-K Filing
Wave Life Sciences issued a press release, though the specific announcement details are not provided in this summary excerpt.
Feb 26
8-K
Wave Life Sciences Ltd. -- 8-K Filing
Wave Life Sciences regained full development and commercialization rights to WVE-006 from GSK, giving the company control of this potential alpha-1 antitrypsin deficiency treatment.
Feb 2
Data updated apr 27, 2026 10:13am
· Source: massive.com